<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    9574657
   </pmid>
   <datecreated>
    <year>
     1998
    </year>
    <month>
     07
    </month>
    <day>
     01
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1998
    </year>
    <month>
     07
    </month>
    <day>
     01
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2004
    </year>
    <month>
     11
    </month>
    <day>
     17
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0148-396X
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       42
      </volume>
      <issue>
       4
      </issue>
      <pubdate>
       <year>
        1998
       </year>
       <month>
        Apr
       </month>
      </pubdate>
     </journalissue>
     <title>
      Neurosurgery
     </title>
     <isoabbreviation>
      Neurosurgery
     </isoabbreviation>
    </journal>
    <articletitle>
     Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the "high-dose hook effect": case report.
    </articletitle>
    <pagination>
     <medlinepgn>
      913-5; discussion 915-6
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE AND IMPORTANCE" nlmcategory="OBJECTIVE">
      We present a case of a giant prolactinoma with a falsely low serum prolactin concentration determined by a two-site chemiluminometric assay. Awareness of the possibility of the "high-dose hook effect" in such cases will prevent preoperative misdiagnosis.
     </abstracttext>
     <abstracttext label="CLINICAL PRESENTATION" nlmcategory="METHODS">
      A patient with a giant invasive pituitary tumor was found preoperatively to have serum prolactin of 31 ng/ml. Pathological examination of the excised tissue, however, demonstrated strong staining for prolactin.
     </abstracttext>
     <abstracttext label="INTERVENTION" nlmcategory="METHODS">
      Serial dilutions of the serum disclosed hyperprolactinemia of 280,000 ng/ml, establishing the presence of the "high-dose hook effect." Treatment with pergolide (Permax; Athena Neurosciences, S. San Francisco, CA) decreased tumor size and lowered serum prolactin by more than 99%.
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      A "high-dose hook effect" needs to be suspected in every patient with a giant pituitary adenoma (&gt;3 cm) and normal serum prolactin. Subsequently assaying the diluted serum will reliably disclose this phenomenon and allow correct diagnosis and therapy.
     </abstracttext>
    </abstract>
    <affiliation>
     Pituitary and Neuroendocrine Center, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0354, USA.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Barkan
      </lastname>
      <forename>
       A L
      </forename>
      <initials>
       AL
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Chandler
      </lastname>
      <forename>
       W F
      </forename>
      <initials>
       WF
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Case Reports
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     Neurosurgery
    </medlineta>
    <nlmuniqueid>
     7802914
    </nlmuniqueid>
    <issnlinking>
     0148-396X
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Dopamine Agonists
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      66104-22-1
     </registrynumber>
     <nameofsubstance>
      Pergolide
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      9002-62-4
     </registrynumber>
     <nameofsubstance>
      Prolactin
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Chemiluminescent Measurements
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Dopamine Agonists
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Magnetic Resonance Imaging
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pergolide
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pituitary Neoplasms
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
     <qualifiername majortopicyn="N">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="Y">
      surgery
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Prolactin
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Prolactinoma
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
     <qualifiername majortopicyn="N">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="Y">
      surgery
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1998
     </year>
     <month>
      5
     </month>
     <day>
      9
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1998
     </year>
     <month>
      5
     </month>
     <day>
      9
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1998
     </year>
     <month>
      5
     </month>
     <day>
      9
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     9574657
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

